These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 27528699)

  • 21. Case report: A family of atypical hemolytic uremic syndrome involving a
    Tasaki Y; Tsujimoto H; Yokoyama T; Sugimoto N; Kitajima S; Fujii H; Hidaka Y; Kato N; Maruyama S; Inoue N; Wada T
    Front Immunol; 2024; 15():1360855. PubMed ID: 38524137
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ImmunoPET of Malignant and Normal B Cells with
    Zettlitz KA; Tavaré R; Knowles SM; Steward KK; Timmerman JM; Wu AM
    Clin Cancer Res; 2017 Dec; 23(23):7242-7252. PubMed ID: 28928164
    [No Abstract]   [Full Text] [Related]  

  • 23. Associations of CFHR1-CFHR3 deletion and a CFH SNP to age-related macular degeneration are not independent.
    Raychaudhuri S; Ripke S; Li M; Neale BM; Fagerness J; Reynolds R; Sobrin L; Swaroop A; Abecasis G; Seddon JM; Daly MJ
    Nat Genet; 2010 Jul; 42(7):553-5; author reply 555-6. PubMed ID: 20581873
    [No Abstract]   [Full Text] [Related]  

  • 24. Fine Mapping Implicates a Deletion of CFHR1 and CFHR3 in Protection from IgA Nephropathy in Han Chinese.
    Xie J; Kiryluk K; Li Y; Mladkova N; Zhu L; Hou P; Ren H; Wang W; Zhang H; Chen N; Gharavi AG
    J Am Soc Nephrol; 2016 Oct; 27(10):3187-3194. PubMed ID: 26940089
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A hybrid CFHR3-1 gene causes familial C3 glomerulopathy.
    Malik TH; Lavin PJ; Goicoechea de Jorge E; Vernon KA; Rose KL; Patel MP; de Leeuw M; Neary JJ; Conlon PJ; Winn MP; Pickering MC
    J Am Soc Nephrol; 2012 Jul; 23(7):1155-60. PubMed ID: 22626820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma.
    Forero-Torres A; de Vos S; Pohlman BL; Pashkevich M; Cronier DM; Dang NH; Carpenter SP; Allan BW; Nelson JG; Slapak CA; Smith MR; Link BK; Wooldridge JE; Ganjoo KN
    Clin Cancer Res; 2012 Mar; 18(5):1395-403. PubMed ID: 22223529
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma.
    Decaup E; Rossi C; Gravelle P; Laurent C; Bordenave J; Tosolini M; Tourette A; Perrial E; Dumontet C; Poupot M; Klein C; Savina A; Fournié JJ; Bezombes C
    Front Immunol; 2019; 10():1943. PubMed ID: 31475004
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Favorable four-yr outcome after renal transplantation in a patient with complement factor H antibody and CFHR1/CFHR3 gene mutation-associated HUS.
    Grenda R; Jarmużek W; Rubik J; Prokurat S; Miklaszewska M; Drozdz D; Zachwieja K; Ardissino G; Hofer J
    Pediatr Transplant; 2015 Sep; 19(6):E130-4. PubMed ID: 26087050
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.
    Goede V; Fischer K; Busch R; Engelke A; Eichhorst B; Wendtner CM; Chagorova T; de la Serna J; Dilhuydy MS; Illmer T; Opat S; Owen CJ; Samoylova O; Kreuzer KA; Stilgenbauer S; Döhner H; Langerak AW; Ritgen M; Kneba M; Asikanius E; Humphrey K; Wenger M; Hallek M
    N Engl J Med; 2014 Mar; 370(12):1101-10. PubMed ID: 24401022
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Obinutuzumab in hematologic malignancies: lessons learned to date.
    Illidge T; Klein C; Sehn LH; Davies A; Salles G; Cartron G
    Cancer Treat Rev; 2015 Nov; 41(9):784-92. PubMed ID: 26190254
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma.
    Racila E; Link BK; Weng WK; Witzig TE; Ansell S; Maurer MJ; Huang J; Dahle C; Halwani A; Levy R; Weiner GJ
    Clin Cancer Res; 2008 Oct; 14(20):6697-703. PubMed ID: 18927313
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
    Davis TA; Grillo-López AJ; White CA; McLaughlin P; Czuczman MS; Link BK; Maloney DG; Weaver RL; Rosenberg J; Levy R
    J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Obinutuzumab: A Review in Rituximab-Refractory or -Relapsed Follicular Lymphoma.
    Dhillon S
    Target Oncol; 2017 Apr; 12(2):255-262. PubMed ID: 28324270
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma.
    Morschhauser F; Marlton P; Vitolo U; Lindén O; Seymour JF; Crump M; Coiffier B; Foà R; Wassner E; Burger HU; Brennan B; Mendila M
    Ann Oncol; 2010 Sep; 21(9):1870-1876. PubMed ID: 20157180
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Deletion of CFHR3 and CFHR1 genes in age-related macular degeneration.
    Spencer KL; Hauser MA; Olson LM; Schmidt S; Scott WK; Gallins P; Agarwal A; Postel EA; Pericak-Vance MA; Haines JL
    Hum Mol Genet; 2008 Apr; 17(7):971-7. PubMed ID: 18084039
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Obinutuzumab for B-cell malignancies.
    Owen CJ; Stewart DA
    Expert Opin Biol Ther; 2014 Aug; 14(8):1197-205. PubMed ID: 24856933
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone.
    Persky DO; Dornan D; Goldman BH; Braziel RM; Fisher RI; Leblanc M; Maloney DG; Press OW; Miller TP; Rimsza LM
    Haematologica; 2012 Jun; 97(6):937-42. PubMed ID: 22271896
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab.
    Bologna L; Gotti E; Manganini M; Rambaldi A; Intermesoli T; Introna M; Golay J
    J Immunol; 2011 Mar; 186(6):3762-9. PubMed ID: 21296976
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study.
    Salles GA; Morschhauser F; Solal-Céligny P; Thieblemont C; Lamy T; Tilly H; Gyan E; Lei G; Wenger M; Wassner-Fritsch E; Cartron G
    J Clin Oncol; 2013 Aug; 31(23):2920-6. PubMed ID: 23835715
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rituximab response in follicular lymphoma is associated with the rs20575 polymorphism in TRAILR1 extrinsic apoptosis trigger.
    Gutiérrez-Cívicos R; Hurtado AM; Torres-Moreno D; Sanchez-Blanco JJ; Español I; Consuegra-Sánchez L; Perez-Ceballos E; Gutiérrez-Meca MD; Jerez A; Conesa-Zamora P
    Pharmacogenet Genomics; 2017 Feb; 27(2):70-77. PubMed ID: 27977511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.